Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycine receptor subunit alpha-2 (GLRA2) is a protein component of the glycine receptor, which is a pentameric ligand-gated chloride ion channel primarily found in the central nervous system, especially during embryonic and early postnatal development[1][2][3][4]. This receptor mediates inhibitory neurotransmission by allowing chloride influx upon activation by glycine, leading to neuronal hyperpolarization and reduced excitability[1][3][4]. The alpha-2 subunit is especially prominent in the developing cortex and participates in critical processes such as cortical interneuron migration, progenitor homeostasis, and modulation of neuronal circuitry[2][3]. Mutations or deletions in GLRA2 are linked to neurodevelopmental disorders, including intellectual disability, autism spectrum disorder, epilepsy, and microcephaly[1][2][3]. Strychnine is a potent competitive antagonist of glycine receptors containing the alpha-2 subunit, while ethanol also modulates receptor function[1][3]. Disruption of GLRA2 function, either via genetic mutation or pharmacological inhibition, compromises inhibitory signaling, potentially resulting in abnormal brain development or increased susceptibility to seizures[2][3].
Modulation or inhibition of chloride ion conductance through receptor antagonism or allosteric modulation (e.g., strychnine blocks the glycine-activated ion channel, leading to increased neuronal excitability)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine receptor subunit alpha-2 (GLRA2).